6-KThe Wire
Telix Pharmaceuticals Ltd files 6-K
Filed Apr 13, 2026 · 2mo ago · Accession 0002007191-26-000017
Plain English
Telix Pharmaceuticals Limited announced a radiopharma collaboration with Regeneron on April 13, 2026. This collaboration is intended to advance the development and commercialization of Telix's prostate cancer imaging agent, Illuccix.
Filing details
- Company
- Telix Pharmaceuticals Ltd
- Ticker
- TLX
- CIK
- 2007191
- Form type
- 6-K
- Filing date
- Apr 13, 2026
- Report date
- Apr 12, 2026
- Document
- k6redwood.htm
- Size
- 1.5 MB
More from TLX
6-KThe WireJul 2, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSMay 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 23, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 21, 20266-KCURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTSApr 20, 20266-KThe WireApr 14, 2026